The study was supported by untied educational grants from Mundipharma; research fellowships from the National Health and Medical Research Council (NHMRC); and the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund.
Several investigators report receiving untied educational grants from Reckitt Benckiser.
Mundipharma and Reckitt Benckiser are both makers of abuse-deterrent opioid formulations.
1. OxyContin tamper-resistant oxycodone tablets. Drugs and Poisons Regulation, April 2015. From the department of health and human services, state government of Victoria, Australia. Available at: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=0CCwQFjACahUKEwiQ3sGU59HIAhUE_WMKHRmwBe4&url=https%3A%2F%2Fwww2.health.vic.gov.au%2FApi%2Fdownloadmedia%2F%257B30745BB2-5BA2-4464-966D-F0D0608A453E%257D&usg=AFQjCNGmB86Ml6qLOZXEZRe_afcUwARf7w&bvm=bv.105454873,d.cGc. Accessed: October 20, 2015
2. Degenhardt L, Bruno R, Ali R, Lintzeris N, Farrell M, Larance, B. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. Drug and Alcohol Dependence. 2015; 151: 56-67. doi:10.1016/j.drugalcdep.2015.02.038
3. Larance B, Lintzeris N, Bruno R et al. The characteristics of a cohort who tamper with prescribed and diverted opioid medications. Journal of Substance Abuse. 2015; 58: 51-61. doi:10.1016/j.jsat.2015.06.001